Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799000 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
- 20
- Study locations
NCT06799000: Recruiting Phase 3 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.
NCT06799000 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 555 participants, roughly in line with the 587-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799000, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Primary Outcome
HiSCR50 is defined as at least a 50% decrease in Abscess and Inflammatory Nodule (AN) count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.
Conditions Studied
Interventions
- DRUG Remibrutinib Dose A
- DRUG Remibrutinib Dose B
- DRUG Placebo 1
- DRUG Placebo 2
Study Locations (20)
California
- Cheryl Effron MD Inc - Anaheim
- Physioseq - Sacramento
- Olive View UCLA Medical Center - Sylmar
- Clinical Trials Research Institute - Thousand Oaks
Florida
- Florida Academic Centers Research and Education LLC - Coral Gables
- University of MiamiHealth System - Miami
- Ziaderm Research LLC - North Miami Beach
Georgia
- Revival Research Institute LLC - Evans
- Gwinnett Clinical Research Center - Snellville
- Immunology-Rheumatology Research - Suwanee
Arkansas
- Johnson Dermatology - Fort Smith
- Arkansas Research Trials - North Little Rock
Michigan
- Michigan Center for Rsrch Company - Clarkston
- Henry Ford Hospital - Detroit
Arizona
- Medical Dermatology Specialists - Phoenix
District of Columbia
- Howard University College of Medicine - Washington D.C.
Illinois
- Illinois Dermatology Institute - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2028-01-18 |
| Phase | Phase 3 |
What NCT06799000 shows while recruiting
NCT06799000 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 587-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 4 interventions - of which Remibrutinib Dose A is the first listed.
NCT06799000 names 20 study sites across 11 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06799000 about?
NCT06799000 is a clinical study titled "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)". The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
What is the current status of trial NCT06799000?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2025-01-31. Estimated completion is 2028-01-18.
What conditions does trial NCT06799000 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06799000?
The interventions under investigation include: Remibrutinib Dose A (DRUG), Remibrutinib Dose B (DRUG), Placebo 1 (DRUG), Placebo 2 (DRUG).
Who is sponsoring clinical trial NCT06799000?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799000 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06799000's enrollment target sits among peer trials
555 9th of 52 higher than 43 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI